Price movement over the last 24 hours
AbbVie Inc vs Advanced Drainage Systems Inc — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Advanced Drainage Systems Inc trades at $145.16 (market cap $11.42B). The key difference: AbbVie Inc is far larger — about 39.4× Advanced Drainage Systems Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | WMS | |
|---|---|---|
Market Cap | $449.91B | $11.42B |
Sector | Health | Industrials |
52-Week High | $261.07 | $175.38 |
52-Week Low | $184.85 | $110.89 |
Enterprise Value | $513.38B | $12.99B |
Dividend Yield | 2.72% | 0.54% |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
Advanced Drainage Systems (WMS) trades at $149.07, down 2.04% over 24 hours. The stock shows strong profitability with a 13.98% net income margin and consistent earnings beats in recent quarters. Technical indicators are bullish overall, with moving averages supporting an uptrend. Recent news includes a dividend increase and mixed analyst sentiment, with a consensus price target of $183.00. Cash flow trends indicate robust operational performance despite a recent dip in net cash flow.
Outlook remains positive due to solid fundamentals and growth in stormwater management demand. Risks include competitive pressures and potential margin compression. The stock presents a moderate buy opportunity with upside to analyst targets, balanced by near-term volatility and sector-specific headwinds.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →